<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83861">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755949</url>
  </required_header>
  <id_info>
    <org_study_id>12-001686</org_study_id>
    <nct_id>NCT01755949</nct_id>
  </id_info>
  <brief_title>Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation and Post AF Ablation</brief_title>
  <official_title>Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the
      rise in CRP which occurs following atrial fibrillation ablation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Three groups of atrial fibrillation patients, 20 per group, will be randomized to receive colchicine or matching placebo for one month, and have intensive monitoring of c-reactive protein during the month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sinus rhythm on ECG</measure>
    <time_frame>One month</time_frame>
    <safety_issue>No</safety_issue>
    <description>All patients will have 12 lead ECG obtained one month after study enrollment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ablation</condition>
  <condition>C Reactive Protein</condition>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation, active drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient (n=10) with chronic atrial fibrillation who are randomized to colchicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic atrial fibrillation,  placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with chronic atrial fibrillation (n=10) who are randomized to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm,  drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with paroxysmal atrial fibrillation presenting for catheter ablation in sinus rhythm (n=10) who are randomized to colchicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with paroxysmal atrial fibrillation presenting for catheter ablation in sinus rhythm (n=10) who are randomized to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, atrial fibrillation, drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients presenting for atrial fibrillation catheter ablation in atrial fibrillation (n=10) who are randomized to colchicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-ablation, atrial fibrillation, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients presenting for atrial fibrillation catheter ablation in atrial fibrillation (n=10) who are randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine, 0.6 mg PO BID</intervention_name>
    <description>Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo</description>
    <arm_group_label>Chronic atrial fibrillation, active drug</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm,  drug</arm_group_label>
    <arm_group_label>Pre-ablation, atrial fibrillation, drug</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug</description>
    <arm_group_label>Chronic atrial fibrillation,  placebo</arm_group_label>
    <arm_group_label>Pre-ablation, sinus rhythm, placebo</arm_group_label>
    <arm_group_label>Pre-ablation, atrial fibrillation, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices.
             Diagnosis of AF will be made based on the 12 -lead surface ECG.

          -  Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the
             electrophysiology laboratory for the procedure in sinus rhythm..

          -  Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting
             in the electrophysiology laboratory in atrial fibrillation .

        Exclusion Criteria:

          1. Abnormal liver function with elevated enzymes&gt; 1.5 times the normal.

          2. Abnormal kidney function with glomerular filtration rate &lt; 50 ml/min

          3. Increased levels of creatine kinase or known myopathy

          4. Neutropenia

          5. Known GI disorders

          6. Women of childbearing age who have not had surgical sterilization and are not using
             oral contraceptives, or who's spouse has not had surgical sterilization will be
             excluded due to the length of the trial and the possibility that they could become
             pregnant after entry.

          7. Pregnant and lactating women

          8. Lactose intolerance

          9. Known sensitivity, allergy, or contraindication to colchicine use -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L. Blackshear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant in Cardiovascular Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana G. Kontras, RN</last_name>
    <phone>904 953-8577</phone>
    <email>kontras.dana@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana g. Kontras, RN</last_name>
      <phone>904-953-8577</phone>
      <email>kontras.dana@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph L. Blackshear</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>colchicine</keyword>
  <keyword>c reactive protein</keyword>
  <keyword>CRP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
